MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Akebia Therapeutics Cash Conversion Cycle 2011-2026 | AKBA
Annual Cash Conversion Cycle Akebia Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 86 | 71.4 | 95.2 | 100 | 236 | 3.39 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.39 K | 71.4 | 663 |
Quarterly Cash Conversion Cycle Akebia Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 175 | 154 | 125 | - | 142 | - | - | - | 92.7 | 75.5 | 92.3 | - | 171 | 201 | 121 | - | 81.5 | 69.4 | 99 | 28.4 | 100 | 37.5 | 193 | 184 | 222 | 222 | 252 | 839 | 28.6 | 31.2 | 50.5 | - | 75.6 | 109 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 839 | 28.4 | 147 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
Adagene
ADAG
|
53.8 | $ 2.75 | -5.5 % | $ 155 M | China |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Amgen
AMGN
|
261 | $ 342.65 | -0.08 % | $ 184 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
235 | $ 81.6 | -0.49 % | $ 1.58 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 70.74 | 2.34 % | $ 9.46 B | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
174 | $ 2.63 | 1.74 % | $ 16.5 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
123 | $ 13.65 | -3.3 % | $ 4.22 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
463 | $ 6.58 | -1.35 % | $ 1.36 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
387 | $ 178.24 | 1.2 % | $ 26 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |